- Home
- PTLO vs REPL Comparison
PTLO vs REPL Comparison
Compare PTLO & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- REPL
- Stock Information
- Founded
- PTLO 1963
- REPL 2015
- Country
- PTLO United States
- REPL United States
- Employees
- PTLO N/A
- REPL N/A
- Industry
- PTLO Restaurants
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PTLO Consumer Discretionary
- REPL Health Care
- Exchange
- PTLO Nasdaq
- REPL Nasdaq
- Market Cap
- PTLO 799.0M
- REPL 851.0M
- IPO Year
- PTLO 2021
- REPL 2018
- Fundamental
- Price
- PTLO $11.34
- REPL $7.89
- Analyst Decision
- PTLO Buy
- REPL Strong Buy
- Analyst Count
- PTLO 7
- REPL 6
- Target Price
- PTLO $14.29
- REPL $20.00
- AVG Volume (30 Days)
- PTLO 1.3M
- REPL 755.6K
- Earning Date
- PTLO 05-06-2025
- REPL 05-15-2025
- Dividend Yield
- PTLO N/A
- REPL N/A
- EPS Growth
- PTLO 43.75
- REPL N/A
- EPS
- PTLO 0.46
- REPL N/A
- Revenue
- PTLO $710,554,000.00
- REPL N/A
- Revenue This Year
- PTLO $13.64
- REPL $31.16
- Revenue Next Year
- PTLO $13.84
- REPL N/A
- P/E Ratio
- PTLO $24.65
- REPL N/A
- Revenue Growth
- PTLO 4.51
- REPL N/A
- 52 Week Low
- PTLO $8.38
- REPL $4.92
- 52 Week High
- PTLO $15.78
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PTLO 36.47
- REPL 21.21
- Support Level
- PTLO $11.55
- REPL $10.17
- Resistance Level
- PTLO $12.46
- REPL $10.78
- Average True Range (ATR)
- PTLO 0.57
- REPL 0.65
- MACD
- PTLO -0.07
- REPL -0.28
- Stochastic Oscillator
- PTLO 1.93
- REPL 0.70
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.